Developer docs
API playgroundTry for free, no card

Search company profiles

Mentari Therapeutics

Full company profile

uuid025vqo4

Namestring
Mentari Therapeutics
Legal namestring
Mentari Therapeutics
Websiteurl
mentaritx.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Mentari Therapeutics is a privately-held biotechnology company developing targeted biologic therapies for migraine prevention. The company is headquartered in Philadelphia, Pennsylvania, and is currently in pre-clinical development with no commercial products on the market. Its scientific focus is on the PACAP (pituitary adenylate cyclase-activating polypeptide) pathway, which it describes as a newly validated and biologically distinct mechanism for migraine that is separate from the established CGRP pathway targeted by currently approved migraine therapeutics.

Mentari's pipeline consists of two lead antibody programs. MT-001 is a monoclonal antibody targeting PACAP and is positioned by the company as potentially best-in-class within the anti-PACAP class. MT-002 is a bispecific antibody engineered to simultaneously block both CGRP and PACAP, intended to deliver superior efficacy compared to either monotherapy approach. Both programs are aimed at the large subpopulation of migraine patients who do not achieve adequate relief from existing anti-CGRP therapies.

The company has no disclosed revenue and operates a pre-commercial business model, relying on corporate communications and investor relations rather than product sales. In May 2026, Mentari announced a definitive all-stock merger agreement with InMed Pharmaceuticals, under which the combined entity will operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market. The transaction remains subject to regulatory approvals and closing conditions. Following regulatory approval, distribution would be expected to follow standard biopharmaceutical channels, including specialty pharmacies, hospital buying groups, and potential partnerships with larger commercial-stage pharmaceutical companies.

Short descriptiontext

Mentari Therapeutics is a privately-held biotechnology company developing biologic antibody therapies — MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) — for migraine prevention in patients with inadequate relief from existing anti-CGRP treatments. The company is pre-clinical and pre-revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
migraine biologics, anti-PACAP antibodies, neurological therapeutics, bispecific antibody therapy, migraine prevention drugs
Industry1 code
PRIMARYHLAKAIAE
Headache & Migraine Medicine
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Therapeutics
No data
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MT-001
Description

Potentially best-in-class anti-PACAP antibody for migraine treatment

mentaritx.com
+1 more record
Core offering1 text field

Mentari Therapeutics is a pre-clinical/clinical-stage biotechnology company developing a portfolio of targeted biologic therapies for the prevention of migraine. Its pipeline comprises two lead drug candidates, MT-001 (an anti-PACAP antibody) and MT-002 (a bispecific antibody blocking both CGRP and PACAP), intended to address the unmet need among migraine patients who do not achieve adequate relief with existing anti-CGRP therapies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mentari Therapeutics is developing a portfolio of targeted biologics for migraine treatment. The company has two lead programs: MT-001, a potentially best-in-class anti-PACAP antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. Both programs aim to address the unmet need in migraine care, as the majority of patients who suffer from migraines are unable to achieve adequate relief with existing anti-CGRP therapies.

Product and service2 records
1MT-001
CategoryDrug candidate / Biologic therapy
Description

Potentially best-in-class anti-PACAP antibody for the prevention of migraine, intended for migraine patients who do not achieve adequate relief from existing anti-CGRP therapies.

2MT-002
CategoryDrug candidate / Biologic therapy
Description

Bispecific antibody designed to block both CGRP and PACAP pathways, with the potential to provide superior efficacy compared to either monotherapy alone in migraine prevention.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

InMed Pharmaceuticals and Mentari Therapeutics announced a definitive merger agreement in an all-stock transaction. Upon closing, the combined entity will operate under the name Mentari Therapeutics and trade on the Nasdaq Capital Market with a new ticker symbol. This merger is intended to advance migraine prevention therapies and remains subject to regulatory approvals and other closing conditions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pfizer acquired Biohaven and now markets Nurtec ODT (rimegepant), a CGRP receptor antagonist for acute and preventive treatment of migraine. Pfizer is the leading large-pharma competitor in the migraine CGRP space and is the type of strategic acquirer that a focused migraine biologics biotech would court as a partner.

TypeEmerging player
Description

Hinge Bio is an early-stage immunology and oncology antibody discovery company that, like Mentari, develops biologic antibody candidates from emerging biology platforms. It represents a comparable pre-commercial antibody-discovery biotech peer in scale and stage, though its therapeutic indications differ from migraine.

TypeDirect peer
Description

AbbVie markets Qulipta (atogepant) for migraine prevention, a CGRP receptor antagonist acquired through its Allergan acquisition. AbbVie competes with Mentari's antibody-based approach through an oral small-molecule CGRP therapy targeting similar migraine patients and prescribing physicians.

TypeDirect peer
Description

Teva markets Ajovy (fremanezumab), an anti-CGRP antibody approved for the preventive treatment of migraine. Teva competes in the same biologic migraine prevention category as Mentari's anti-PACAP and bispecific programs and shares the same prescriber and payor audiences.

TypeDirect peer
Description

Novartis co-commercializes Aimovig with Amgen outside the United States and is a primary global commercial partner for the leading anti-CGRP migraine antibody. Novartis's neurology footprint and migraine franchise make it a likely strategic competitor or acquirer for PACAP-targeting biologics.

TypeOthers
Description

Ionis is a leading antisense oligonucleotide platform company with multiple CNS and neurology programs (including migraine-adjacent neurology). While its modality is antisense rather than antibodies, it is frequently benchmarked as a comparable CNS-focused targeted biologics platform with a public listing and similar development timeline dynamics.

TypeEmerging player
Description

Annexon is a clinical-stage biotechnology company developing antibody therapeutics for neuroinflammatory and neurodegeneration disorders (e.g., Annexin A1 path). Like Mentari, Annexon is an early-stage antibody biotech focused on neurology indications, with comparable pipeline-stage profile even though its target biology is distinct.

TypeDirect peer
Description

Eli Lilly commercializes Emgality (galcanezumab), an anti-CGRP antibody for migraine prevention, and has publicly disclosed PACAP-pathway antibody programs. Mentari's MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) compete directly with the same migraine biologic targets and overlap heavily in prescriber audience.

TypeDirect peer
Description

Amgen co-commercializes Aimovig (erenumab) with Novartis, the first-to-market anti-CGRP antibody for migraine prevention. Amgen is the established reference competitor for monoclonal antibodies targeting the migraine CGRP pathway and operates at scale that any new entrant must compete against commercially.

TypeDirect peer
Description

Lundbeck markets Vyepti (eptinezumab), an IV anti-CGRP antibody for migraine prevention acquired through its purchase of Alder Biopharmaceuticals. Vyepti is one of the four approved anti-CGRP migraine antibodies and competes for the same prescriber share that Mentari would target post-approval.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mentari Therapeutics

Neurological Therapeuticsmentaritx.com

Mentari Therapeutics is a privately-held biotechnology company developing biologic antibody therapies — MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) — for migraine prevention in patients with inadequate relief from existing anti-CGRP treatments. The company is pre-clinical and pre-revenue.

What Mentari Therapeutics does

Mentari Therapeutics is a privately-held biotechnology company developing targeted biologic therapies for migraine prevention. The company is headquartered in Philadelphia, Pennsylvania, and is currently in pre-clinical development with no commercial products on the market. Its scientific focus is on the PACAP (pituitary adenylate cyclase-activating polypeptide) pathway, which it describes as a newly validated and biologically distinct mechanism for migraine that is separate from the established CGRP pathway targeted by currently approved migraine therapeutics.

Mentari's pipeline consists of two lead antibody programs. MT-001 is a monoclonal antibody targeting PACAP and is positioned by the company as potentially best-in-class within the anti-PACAP class. MT-002 is a bispecific antibody engineered to simultaneously block both CGRP and PACAP, intended to deliver superior efficacy compared to either monotherapy approach. Both programs are aimed at the large subpopulation of migraine patients who do not achieve adequate relief from existing anti-CGRP therapies.

The company has no disclosed revenue and operates a pre-commercial business model, relying on corporate communications and investor relations rather than product sales. In May 2026, Mentari announced a definitive all-stock merger agreement with InMed Pharmaceuticals, under which the combined entity will operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market. The transaction remains subject to regulatory approvals and closing conditions. Following regulatory approval, distribution would be expected to follow standard biopharmaceutical channels, including specialty pharmacies, hospital buying groups, and potential partnerships with larger commercial-stage pharmaceutical companies.

Mentari Therapeutics firmographics

Firmographics
Name
Mentari Therapeutics
Legal name
Mentari Therapeutics
Website
https://mentaritx.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Mentari Therapeutics is a privately-held biotechnology company developing biologic antibody therapies — MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) — for migraine prevention in patients with inadequate relief from existing anti-CGRP treatments. The company is pre-clinical and pre-revenue.
Ownership category
akta.pro rank

Mentari Therapeutics industry classification

Industry
Product category
Neurological Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAIAE
Headache & Migraine Medicine

Keywords

  • Migraine biologics
  • Anti-PACAP antibodies
  • Neurological therapeutics
  • Bispecific antibody therapy
  • Migraine prevention drugs

Where Mentari Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Markets served

Mentari Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels3 records

Mentari Therapeutics product offering

Product offering

Core offering

Mentari Therapeutics is a pre-clinical/clinical-stage biotechnology company developing a portfolio of targeted biologic therapies for the prevention of migraine. Its pipeline comprises two lead drug candidates, MT-001 (an anti-PACAP antibody) and MT-002 (a bispecific antibody blocking both CGRP and PACAP), intended to address the unmet need among migraine patients who do not achieve adequate relief with existing anti-CGRP therapies.

Product overview

Mentari Therapeutics is developing a portfolio of targeted biologics for migraine treatment. The company has two lead programs: MT-001, a potentially best-in-class anti-PACAP antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. Both programs aim to address the unmet need in migraine care, as the majority of patients who suffer from migraines are unable to achieve adequate relief with existing anti-CGRP therapies.

Differentiator

Problem solved

Functional benefit

Brands

  • MT-001: Potentially best-in-class anti-PACAP antibody for migraine treatment
  • MT-002

Products and services

  • MT-001 Potentially best-in-class anti-PACAP antibody for the prevention of migraine, intended for migraine patients who do not achieve adequate relief from existing anti-CGRP therapies.
  • MT-002 Bispecific antibody designed to block both CGRP and PACAP pathways, with the potential to provide superior efficacy compared to either monotherapy alone in migraine prevention.

Companies that use Mentari Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Mentari Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Mentari Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • InMed PharmaceuticalscoreStrategic or Co-development Partner · 1 May 2026InMed Pharmaceuticals and Mentari Therapeutics announced a definitive merger agreement in an all-stock transaction. Upon closing, the combined entity will operate under the name Mentari Therapeutics and trade on the Nasdaq Capital Market with a new ticker symbol. This merger is intended to advance migraine prevention therapies and remains subject to regulatory approvals and other closing conditions.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Mentari Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pfizer: Pfizer acquired Biohaven and now markets Nurtec ODT (rimegepant), a CGRP receptor antagonist for acute and preventive treatment of migraine. Pfizer is the leading large-pharma competitor in the migraine CGRP space and is the type of strategic acquirer that a focused migraine biologics biotech would court as a partner.
  • AbbVie: AbbVie markets Qulipta (atogepant) for migraine prevention, a CGRP receptor antagonist acquired through its Allergan acquisition. AbbVie competes with Mentari's antibody-based approach through an oral small-molecule CGRP therapy targeting similar migraine patients and prescribing physicians.
  • Teva Pharmaceutical: Teva markets Ajovy (fremanezumab), an anti-CGRP antibody approved for the preventive treatment of migraine. Teva competes in the same biologic migraine prevention category as Mentari's anti-PACAP and bispecific programs and shares the same prescriber and payor audiences.
  • Novartis: Novartis co-commercializes Aimovig with Amgen outside the United States and is a primary global commercial partner for the leading anti-CGRP migraine antibody. Novartis's neurology footprint and migraine franchise make it a likely strategic competitor or acquirer for PACAP-targeting biologics.
  • Eli Lilly: Eli Lilly commercializes Emgality (galcanezumab), an anti-CGRP antibody for migraine prevention, and has publicly disclosed PACAP-pathway antibody programs. Mentari's MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) compete directly with the same migraine biologic targets and overlap heavily in prescriber audience.
  • Amgen: Amgen co-commercializes Aimovig (erenumab) with Novartis, the first-to-market anti-CGRP antibody for migraine prevention. Amgen is the established reference competitor for monoclonal antibodies targeting the migraine CGRP pathway and operates at scale that any new entrant must compete against commercially.
  • Lundbeck: Lundbeck markets Vyepti (eptinezumab), an IV anti-CGRP antibody for migraine prevention acquired through its purchase of Alder Biopharmaceuticals. Vyepti is one of the four approved anti-CGRP migraine antibodies and competes for the same prescriber share that Mentari would target post-approval.

Emerging players

  • Hinge Bio: Hinge Bio is an early-stage immunology and oncology antibody discovery company that, like Mentari, develops biologic antibody candidates from emerging biology platforms. It represents a comparable pre-commercial antibody-discovery biotech peer in scale and stage, though its therapeutic indications differ from migraine.
  • Annexon: Annexon is a clinical-stage biotechnology company developing antibody therapeutics for neuroinflammatory and neurodegeneration disorders (e.g., Annexin A1 path). Like Mentari, Annexon is an early-stage antibody biotech focused on neurology indications, with comparable pipeline-stage profile even though its target biology is distinct.

Others

  • Ionis Pharmaceuticals: Ionis is a leading antisense oligonucleotide platform company with multiple CNS and neurology programs (including migraine-adjacent neurology). While its modality is antisense rather than antibodies, it is frequently benchmarked as a comparable CNS-focused targeted biologics platform with a public listing and similar development timeline dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Mentari Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mentari Therapeutics leadership team

Management profile

Number of profiles

Mentari Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mentari Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mentari Therapeutics

What does Mentari Therapeutics do?

Mentari Therapeutics is a pre-clinical/clinical-stage biotechnology company developing a portfolio of targeted biologic therapies for the prevention of migraine. Its pipeline comprises two lead drug candidates, MT-001 (an anti-PACAP antibody) and MT-002 (a bispecific antibody blocking both CGRP and PACAP), intended to address the unmet need among migraine patients who do not achieve adequate relief with existing anti-CGRP therapies.

Is Mentari Therapeutics a public or private company?

Mentari Therapeutics is a private company. It is classified as unknown and is currently operating.

When was Mentari Therapeutics founded?

Mentari Therapeutics was founded in -1. It employs 11 to 50 people.

Where is Mentari Therapeutics based?

Mentari Therapeutics is headquartered in Waltham, United States, in the North America region.

Who are Mentari Therapeutics's main competitors?

Direct peers on record are Pfizer, AbbVie, Teva Pharmaceutical, Novartis, Eli Lilly, Amgen and Lundbeck. Emerging players are Hinge Bio and Annexon. Ionis Pharmaceuticals is listed as an others.

Does Mentari Therapeutics have an API?

No public API is recorded for Mentari Therapeutics.

What industry is Mentari Therapeutics in?

Mentari Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAKAIAE, Headache & Migraine Medicine. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comMentari at Jefferies Global Healthcare Conference: migraine push gains paceMentari outlined its migraine franchise strategy at the Jefferies Global Healthcare Conference, citing a $490 million reverse merger and cash runway into 2029. The company is advancing five programs, led by 001 (PACAP antibody) and 002 (PACAP-CGRP bispecific), with a Q1 2027 regulatory filing for 002 and mid-2027 data for 001.Investing.comWedbush initiates Mentari Therapeutics stock at OutperformWedbush initiated coverage on Mentari Therapeutics with an Outperform rating and a $33 price target. The firm sees MT-001 and MT-002 as having blockbuster potential, with a base case of $1.36 billion in fiscal 2035 revenue. Other analysts also initiated buy ratings.MarketScreenerWedbush Initiates Mentari Therapeutics at Outperform With $33 Price TargetWedbush initiated Mentari Therapeutics at Outperform with a $33 price target. The company will change its ticker from INM to MTRI on November 9, 2026. The stock is trading at $15.61, up 27.94% over five days.American Banking and Market NewsStifel Nicolaus Begins Coverage on Mentari Therapeutics (NASDAQ:MTRI)Stifel Nicolaus began coverage on Mentari Therapeutics with a buy rating and a $30 price target, implying 92.18% upside from current price. The stock opened at $15.61, and major shareholder Adar1 Capital Management purchased 2,640 shares at $13.10 each.Investing.comStifel initiates Mentari Therapeutics stock with buy ratingStifel initiated coverage on Mentari Therapeutics with a buy rating and a $30 price target, implying nearly 90% upside from the current price. The company is developing two migraine products, MT-001 and MT-002, licensed from Paragon, with Jefferies also rating it a buy at the same target.Business & FinancialMentari Therapeutics To Present At Upcoming Investor ConferencesMentari Therapeutics will present at three upcoming investor conferences in November, including Guggenheim, Stifel, and Jefferies. The company develops anti-PACAP and anti-CGRP therapies for migraine, with lead programs MT-001 and MT-002. Live webcasts and archived recordings will be available for 90 days.Stock TitanMentari Therapeutics to Join 3 November Investor ConferencesMentari Therapeutics management will present at three investor conferences in November, starting November 9. The company, developing migraine-prevention therapies, will also provide live webcasts and archived recordings of the events.Startup ResearcherMentari Therapeutics Closes InMed Merger and US$490 Million FinancingMentari Therapeutics closed its merger with InMed Pharmaceuticals and began Nasdaq trading on November 9, 2026, under ticker MTRI. The company completed two private financings totaling US$490 million, led by Fairmount, to fund operations into 2029. Its migraine-prevention pipeline includes MT-001 and MT-002, with initial data expected in mid-2027.Pulse 2.0Mentari Therapeutics Completes InMed Pharmaceuticals Merger Following Approximately $490 Million In FinancingMentari Therapeutics completed its merger with InMed Pharmaceuticals after raising about $490 million in private financing. The combined company will trade on Nasdaq under MTRI on November 9, 2026, and will pursue its migraine prevention programs MT-001 and MT-002.Dealroom.coCannabis firm InMed becomes migraine biotech Mentari in merger backed by $490MInMed Pharmaceuticals merged with Mentari Therapeutics, converting InMed into a vehicle for Mentari's migraine-prevention pipeline. The combined company, trading as MTRI, is backed by roughly $490 million in private financings, including $50 million in convertible notes. Mentari's lead programs target migraine, with development funding through 2029.